[HTML] frontiersin.org

[HTML][HTML] Novel 1, 2, 3-triazole erlotinib derivatives as potent IDO1 inhibitors: Design, drug-target interactions prediction, synthesis, biological evaluation, molecular …

GQ Xu, XQ Gong, YY Zhu, XJ Yao, LZ Peng… - Frontiers in …, 2022 - frontiersin.org
Indoleamine 2, 3-dioxygenase 1 (IDO1) plays a predominant role in cancer immunotherapy
which catalyzes the initial and rate limiting steps of the kynurenine pathway as a key …
被引用次数：12 相关文章
[HTML] nih.gov

[HTML][HTML] Novel 1, 2, 3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular …

GQ Xu, XQ Gong, YY Zhu, XJ Yao, LZ Peng… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Abstract Indoleamine 2, 3-dioxygenase 1 (IDO1) plays a predominant role in cancer
immunotherapy which catalyzes the initial and rate limiting steps of the kynurenine pathway …

Novel 1, 2, 3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking …

GQ Xu, XQ Gong, YY Zhu, XJ Yao, LZ Peng… - Frontiers in …, 2022 - europepmc.org
Abstract Indoleamine 2, 3-dioxygenase 1 (IDO1) plays a predominant role in cancer
immunotherapy which catalyzes the initial and rate limiting steps of the kynurenine pathway …

Novel 1, 2, 3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking …

GQ Xu, XQ Gong, YY Zhu, XJ Yao… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Indoleamine 2, 3-dioxygenase 1 (IDO1) plays a predominant role in cancer immunotherapy
which catalyzes the initial and rate limiting steps of the kynurenine pathway as a key …